This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...
The study examines the global policy landscape for invasive fungal infections, identifies key policy gaps, and underscores the need for stronger policy...
CRA is a proud sponsor of the largest annual gathering of Medical Affairs professionals, globally. Ayushman Ghosh and Brooke Bonet present the roundtable...
CRA is a proud sponsor of Paris Arbitration Week, an international and dynamic event, involving practitioners from all over the world. For more information on...
